https://www.selleckchem.com/pr....oducts/pf-03084014-p
As a result, cisplatin-resistant cells were more resistant to PARP inhibitor (PARPi) monotherapy. Moreover, when PARPi was given in combination with cisplatin, it exerted an additive/synergistic effect, and reduced the cisplatin dose for cytotoxicity. These results suggest that treatment of cisplatin-refractory patients may benefit from low-dose cisplatin therapy combined with PARPi.Leukemia is a hematological malignancy that originates from hematopoietic stem cells in the bone marrow. Significant progress has made in und
Like
Comment
Share
